2型糖尿病患者的强化血压控制
该研究纳入中国145个临床中心、年龄≥50岁、收缩压升高且心血管风险增加的2型糖尿病患者12,821例,随机接受强化治疗(目标收缩压<120 mmHg)或标准治疗(目标收缩压<140 mmHg),最长5年。主要终点为非致死性卒中、非致死性心肌梗死、心力衰竭治疗或住院、心血管原因死亡的复合终点。中位随访4.2年,强化组主要终点事件393例(1.65/100人年)vs 标准组492例(2.09/100人年),HR 0.79(95%CI 0.69–0.90,P<0.001)。严重不良事件两组相似,但强化组症状性低血压和高钾血症更常见。
要点
- 2型糖尿病心血管高危患者强化降压至收缩压<120 mmHg,主要心血管复合终点HR 0.79(95%CI 0.69–0.90,P<0.001)。
- 随访1年时强化组平均收缩压121.6 mmHg(中位数118.3 mmHg),标准组133.2 mmHg(中位数135.0 mmHg)。
- 中位随访4.2年,强化组主要终点事件1.65/100人年 vs 标准组2.09/100人年。
- 严重不良事件两组相似,但强化组症状性低血压和高钾血症发生更频繁。
- 研究人群为年龄≥50岁、收缩压升高且心血管风险增加的2型糖尿病患者,来自中国145个临床中心。
适用人群与场景
- 年龄50岁或以上的2型糖尿病患者,收缩压升高且心血管疾病风险增加,来自中国145个临床中心。
处置流程与药物剂量
- 强化治疗组目标收缩压低于120 mmHg,标准治疗组目标收缩压低于140 mmHg,治疗最长5年。
研究设计与关键结果
- 多中心随机对照试验,纳入12,821例患者(强化组6414例,标准组6407例),2019年2月至2021年12月入组,女性5803例(45.3%),平均年龄63.8±7.5岁。
- 随访1年时强化组平均收缩压121.6 mmHg(中位数118.3 mmHg),标准组平均133.2 mmHg(中位数135.0 mmHg)。
- 中位随访4.2年,主要终点事件强化组393例(1.65/100人年)vs 标准组492例(2.09/100人年),HR 0.79(95%CI 0.69–0.90,P<0.001)。
- 严重不良事件发生率两组相似;症状性低血压和高钾血症在强化治疗组比标准治疗组更常见。
证据类型、等级与局限
- 随机对照试验;基金来源包括中国科学技术部国家重点研发计划等;临床试验注册号NCT03808311。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对年龄≥50岁、收缩压升高且心血管风险增加的2型糖尿病患者,强化降压至收缩压<120 mmHg较<140 mmHg可降低主要心血管事件风险,但需注意症状性低血压和高钾血症更常见。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear.
METHODS: We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood pressure, and an increased risk of cardiovascular disease at 145 clinical sites across China. Patients were randomly assigned to receive intensive treatment that targeted a systolic blood pressure of less than 120 mm Hg or standard treatment that targeted a systolic blood pressure of less than 140 mm Hg for up to 5 years. The primary outcome was a composite of nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes. Multiple imputation was used for missing outcome data, with an assumption that the data were missing at random.
RESULTS: Of 12,821 patients (6414 patients in the intensive-treatment group and 6407 in the standard-treatment group) enrolled from February 2019 through December 2021, 5803 (45.3%) were women; the mean (±SD) age of the patients was 63.8±7.5 years. At 1 year of follow-up, the mean systolic blood pressure was 121.6 mm Hg (median, 118.3 mm Hg) in the intensive-treatment group and 133.2 mm Hg (median, 135.0 mm Hg) in the standard-treatment group. During a median follow-up of 4.2 years, primary-outcome events occurred in 393 patients (1.65 events per 100 person-years) in the intensive-treatment group and 492 patients (2.09 events per 100 person-years) in the standard-treatment group (hazard ratio, 0.79; 95% confidence interval, 0.69 to 0.90; P<0.001). The incidence of serious adverse events was similar in the treatment groups. However, symptomatic hypotension and hyperkalemia occurred more frequently in the intensive-treatment group than in the standard-treatment group.
CONCLUSIONS: Among patients with type 2 diabetes, the incidence of major cardiovascular events was significantly lower with intensive treatment targeting a systolic blood pressure of less than 120 mm Hg than with standard treatment targeting a systolic blood pressure of less than 140 mm Hg. (Funded by the National Key Research and Development Program of the Ministry of Science and Technology of China and others; BPROAD ClinicalTrials.gov number, NCT03808311.).
参考来源
- Bi Y, Li M, Liu Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2024. PMID: 39555827. doi:10.1056/NEJMoa2412006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。